AR and cancer: In luminal FMCs as well, AR overexpression was associated with favorable outcome in terms of cancer-specific survival (HR = 0.38, 95% CI: 0.19–0.74; p = 0.017) and overall survival (HR = 0.46, 95% CI: 0.25–0.82, p = 0.024).